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Under normal physiological conditions and in response to
chemotherapeutic drugs or irradiation, cells die by a morphologi-
cally distinct event known as apoptosis (Kerr et al, 1972; Koshiji
et al, 1997). Apoptosis is a genetically regulated process that in
balance with cell proliferation is required by normal tissues for
remodelling, proper development and function (Kerr et al, 1972).
An alteration in the activity of genes controlling the cell cycle
or apoptosis can lead to pathological changes that may result
in degenerative disease or cancer (Vaux et al, 1988; Lane, 1992;
Katada et al, 1997). 
Both p53 and bcl-2 gene products are involved in the regulation
of cell cycle and apoptosis. The p53 tumour suppressor gene
encodes a 53 kDa nuclear phosphoprotein. This protein functions
as a nuclear transcription factor and activates other genes involved
in growth arrest and apoptosis in response to DNA damage and
other cellular insults (Lane, 1992; Leland and Kastan, 1994;
Kagawa et al, 1997; Levin, 1997). The loss of functional wild-type
p53 protein due to mutation or allelic deletion of the gene signifi-
cantly alters suppressor activity and increases genomic instability
(Lane, 1992; Leland and Kastan, 1994; Paules et al, 1995). The
bcl-2 oncogene encodes a 25 kDa integral membrane protein that
is involved in the regulation of programmed cell death by
inhibiting apoptosis (Hockenbery et al, 1990). Bcl-2 protein
allows cells to accumulate by prolonging their life span
(Hockenbery et al, 1990; Liu et al, 1991) and this effect may
contribute to neoplastic development (Vaux et al, 1988). Studies
have demonstrated that high levels of bcl-2 protect cells from
apoptosis induced by a variety of chemotherapeutic agents (Inada
et al, 1997; Miyake et al, 1998; Zhang et al, 1999) and irradiation
(Rupnow et al, 1998). The precise biochemical function of bcl-2 is
still under investigation and it is likely that the inter-relationship
between bcl-2 family proteins and their relative ratios will eventually
determine cell susceptibility to undergo apoptosis or survive after an
apoptotic signal (Oltvai et al, 1993; Reed, 1994; Sato et al, 1994).
The Oesophageal Unit in St James’s Hospital and Trinity
College Dublin has reported in a randomised trial that neaodjuvant
chemoradiotherapy prior to resectional surgery results in a patho-
logical complete response rate of 25% and improved survival
compared to surgery alone (Walsh et al, 1996). Approximately
60% of patients have no response to neoadjuvant therapy. There is
a need to identify molecular factors predicting response or resis-
tance to this treatment. The purpose of this study was 2-fold: first,
to investigate the frequency of apoptosis and cell proliferation in
oesophageal adenocarcinoma and the influence of p53 and bcl-2,
and secondly, to determine the influence of neoadjuvent chemo-
radiotherapy on these parameters. 
MATERIALS AND METHODS 
Patients 
Archival formalin-fixed paraffin-embedded tissue samples from
42 patients (32 male, 10 female) with primary oesophageal adeno-
carcinoma was included in this study. Patient age ranged from 48
to 77 years (64.3 ± 7.6 mean ± SD, 66 median). All patients had
oesophagogastro-endoscopy and histological confirmation of
diagnosis prior to treatment with chemotherapy (cisplatin and 
5-fluorouracil) and radiotherapy (CRX) followed by oesophagec-
tomy. Surgery was undertaken at a median of 4 (range 3–6) weeks
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curative intent and patients with T4 disease or metastatic disease
were excluded. 
Histopathological examination 
Diagnostic biopsy and resection specimens were fixed in 10%
buffered formalin, routinely processed and embedded in paraffin.
Haematoxylin and eosin slides were reviewed and sequential 4 µ m
sections were used for immunohistochemistry. Tumours were
staged according to the TNM system. Patients were defined as
complete pathological response (CPR) to CRX when no micro-
scopic tumour cells were identified at resection (n = 9). Patients
(n = 29) were defined as non-responders (NPR) to CRX when
there was no evidence of pathological response in the resection
specimen e.g. the presence of lymph node metastasis, lympho-
vascular permeation and no down-staging (i.e. pT3) compared to
pre-treatment status. A third intermediate group (n = 4) was
defined as having a major pathological response (MPR) to CRX.
These patients were all lymph node-free and had microscopic
residual tumour cells only in any part of the oesophageal wall. For
the purpose of statistical analysis CPR and MPR data are
combined to one group (n = 13) versus NPR (n = 29). 
Assessment of apoptosis 
In situ terminal deoxynucleotide transferase (TdT) method was
used for identification of apoptotic cells and bodies in paraffin
tissue sections using Apoptag® peroxidase in situ apoptosis detec-
tion kit (S7100) (Intergen Company). Following the manufac-
turer’s instructions 4 µ m sections were deparaffinised, rehydrated
and placed in 10 mM citrate buffer pH at 6.0 and gently boiled
for 10 min in a microwave oven. Sections were incubated with 20
µ gm l –1 proteinase K at room temperature for 10 min followed
by exposure to 3% hydrogen peroxide in PBS to quench endoge-
nous peroxidase activity. The sections were then treated with
terminal transferase enzyme and digoxigenin-labelled nucleotides.
Apoptotically fragmented DNA that have been labelled with the
digoxigenin nucleotide was then allowed to bind an anti-digoxigen
antibody that is conjugated to peroxidase molecules. The reaction
products of peroxidase were visualised with 3′ -3′ diaminobenzidine
(DAB). After the color reaction, sections were counterstained with
methyl green. Unstained rat mammary glands (Apoptag® positive
control slides (S7115), Intergen Company) were used as posi-
tive controls. Omission of the TdT during the staining procedure
provided negative controls. The number of apoptotic cells and
bodies in a total of 2000 tumour cells were counted and the
percentage positivity recorded as the apoptotic index (AI). 
Immunohistochemistry 
Sections of the same part of the tumour used for detection of apop-
totic cells were used to assess Ki-67, p53 and bcl-2 immunoreac-
tivity by standard avidin–biotin complex method. Sections were
incubated with polyclonal anti-Ki-67, monoclonal mouse anti-
p53-DO7 and anti-bcl-2 clone 124, (Dako A/S, Denmark) dilution
1:50–overnight at 4˚C. Biotinylated swine anti-rabbit and rabbit
anti-mouse (1:300 dilution–30 min) were used as a secondary anti-
body. The colour reaction product was obtained with DAB and a
haematoxylin counterstained. Sections of human tonsil, colon
adenocarcinoma and follicular lymphoma known to be positive for
ki-67, p53 and bcl-2 were used as positive controls. Omission of
the primary antibody provided negative controls. Out of 2000
tumour cells the number showing moderate to intense immuno-
staining was counted and the percentage positivity recorded as the
labelling index (LI). Tumours demonstrating weak immunoposi-
tivity with LI < 5% were considered to be negative for p53 or bcl-2. 
Statistical analysis 
All statistical calculations were carried out with the StatView soft-
ware package (Abacus Concepts, Berkeley, CA). The significance
of association among variables (AI, Ki-67 LI, p53 and bcl-2
expression) and the clinicopathological factors including tumour
differentiation, depth of invasion and lymph node status was deter-
mined by Mann–Whitney or Kruskal–Wallis tests. The association
between p53, bcl-2 expression and type of response to CRX was
determined by Fisher exact test. For paired comparison of AI and
Ki-67 LI pre- to post-CRX values Wilcoxon test was used.
Statistical significance was defined as P < 0.05. 
RESULTS 
Apoptotic index, Ki-67 labelling index, p53 and bcl-2
expression in oesophageal adenocarcinomas prior to
chemoradiotherapy (Table 1) 
Apoptotic cells and bodies were detected among viable tumour
cells in all adenocarcinoma cases examined in this study. The
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Table 1 Apoptotic index, Ki-67 labelling index, p53 and bcl-2 expression in oesophageal adenocarcinomas prior to chemoradiotherapy 
Parameters No. of cases Apoptotic index  P value Ki-67 labelling index  P value 
Mean ± SD/Median Mean ± SD/Median
Response to CRX 
CPR and MPR 13 0.83 ± 0.31/0.75  35.1±15.7/33.7 
NPR 29 0.60 ± 0.29/0.55 0.01  38.8±12.0/37.1 0.35 
p53 expression 
negative tumours 15 0.57 ± 0.34/0.52 31.9±7.8/35.2 
positive tumours 27 0.73 ± 0.29/0.65 0.07 40.9±14.5/41.9 0.01 
Bcl-2 expression 
negative tumours 33 0.67 ± 0.32/0.64 37.5±13.8/37.2 
positive tumours 9 0.68 ± 0.32/0.56  0.79 38.3±10.7/36.0 0.80 
Tumour differentiation 
well/moderate 30 0.64 ± 0.29/0.57  38.3±12.6/36.7 
poor 12 0.74 ± 0.36/0.71 0.26  36.0±15.4/34.6 0.48 occurrence of spontaneous apoptosis in pre-CRX tumours (n = 42)
ranged from 0.16 to 1.60% (0.68 ± 0.32 mean ± SD; 0.63 median).
The proliferation index, assessed by Ki-67 LI, ranged from 2 to
64.8% (38.1 ± 13.2 mean ± SD; 37.1 median). p53 and bcl-2
protein expression was detected in 64.2% (27/42) and 21.4%
(9/42) of tumours, respectively. 
A significant (P = 0.01) association was observed between the
apoptotic index and the type of response to CRX. Tumours that
responded completely to preoperative CRX and those that showing
a major pathological response had a higher apoptotic index in pre-
treatment tumour samples compared to tumours with no evidence
of pathological response (Figures 1 and 2A). There was no associ-
ation between the tumour response or resistance to CRX and Ki-67
expression. There was no significant association between the
apoptotic index and p53 or bcl-2 expression. Accumulation of p53
protein in tumour samples was significantly associated with high
Ki-67 expression (P = 0.01). 
Expression of p53 and bcl-2 and type of response to
chemoradiotherapy (Table 2) 
Pre-treatment tumour samples (n = 9) of the subsequent complete
pathological responders to CRX demonstrated 77.7% (7/9) and
11.1% (1/9) p53 and bcl-2 immunopositivity, respectively. Pre-
treatment tumour samples (n = 4) of the subsequent major patho-
logical responders were 50% (2/4) p53 and 50% (2/4) p53 and
50% (2/4) bcl-2 immunopositive, respectively. Tumours (n = 29)
that did not respond to CRX expressed p53 in 62% (18/29) of
cases and bcl-2 in 20.6% (6/29). Expression of p53 or bcl-2 did
not statistically associate with tumour response or resistance to
CRX. 
Apoptotic index, Ki-67 labelling index, p53 and bcl-2
expression in oesophageal adenocarcinoma after
chemoradiotherapy (Table 3) 
It was not possible to determine the apoptotic or proliferation
indices in residual carcinomas of patients having a major patholog-
ical response to CRX (n = 4) due to an insufficient number
of residual tumour cells. Expression of p53 and bcl-2 was detected
in 25% (1/4) of residual tumours. In residual carcinomas of
patients having no pathological response to CRX (n = 29) the
apoptotic index was significantly increased by CRX compared to
its pre-treatment value (P < 0.0001) (Figure 2B), and the prolifera-
tion index (Ki-67 LI) was significantly decreased (P = 0.0003). The
expression of p53 and bcl-2 was detected in 79.3% (23/29) and
24.1% (7/29) of tumours, respectively. Neither p53 nor bcl-2 expres-
sion was statistically associated with the apoptotic or proliferation
index. 
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Figure 1 In situ labelling of apoptotic tumour cells; oesophageal
adenocarcinoma pre-treatment. This patient had a complete pathological
response to chemoradiotherapy. Apoptotic tumour cells are characterised by
condensed chromatin and nuclear fragmentation represented by dark black
staining (arrows, magnification × 400). The apoptotic index is significantly
higher in chemoradio-sensitive compare to -resistant tumours 
Figure 2 In situ labelling of apoptotic tumour cells of a patient with
oesophageal adenocarcioma: (A) prior to; (B) after chemoradiotherapy.
This patient showed no pathological response to neoadjuvant therapy.
Apoptotic tumour cells are characterised by condensed chromatin and nuclear
fragmentation represented by dark black staining (arrows, magnification
(A) × 250 and (B) × 400). Apoptotic index is significantly higher in resected
tumour following chemoradiotherapy 
Table 2 Expression of p53 and bcl-2 and type of response to
chemoradiotherapy 
Parameters CPR and MPR NPR P value 
P53 expression 
negative tumours 4 11 
positive tumours 9 18 0.73 
Bcl-2 expression 
negative tumours 10 23 
positive tumours 3 6 0.9Apoptotic index, Ki-67 labelling index, p53 and bcl-2
expression and clinicopathological parameters 
Both before and after CRX, no significant association was
observed between the apoptotic or proliferation index and tumour
differentiation. Post-CRX, increasing depth of invasion (pT) of
residual tumours was associated with an increasing apoptotic index
(P = 0.02) and a high Ki-67 expression was significantly associated
with the presence of lymph node metastasis (P = 0.008). 
DISCUSSION 
Neoadjuvant chemotherapy with and without radiotherapy can
result in complete or major pathological responses and improve
local control and overall survival of patients with cancer (Walsh
et al, 1996; Giatromanolaki et al, 1999; Kollmannsberger et al,
2000). The process of programmed cell death is considered a
mechanism to counter proliferation activity (Katada et al, 1997)
and is a potential predictor of treatment efficacy (Scott et al, 1998;
Logsdon et al, 1999; Cameron et al, 2000; Rodel et al, 2000). In
the present study the degree of apoptosis was analysed in relation
to clinicopathological parameters, cell proliferation activity, and
the expression of apoptotic/cell-cycle-related proteins. 
Apoptotic tumour cells were visualised by enzymatic labelling of
fragmented DNA with a terminal transferase reaction. The method-
ology facilitates detection of early and late stages of the apoptotic
cells in tissue sections. The results from this study indicate that an
increased rate of spontaneous apoptosis in oesophageal adenocarci-
nomas may be a prognostic biomarker for chemoradiotherapy in
patients with oesophageal adenocarcinoma. Tumours with a high
apoptotic index were more sensitive to chemotherapy and radia-
tion therapy than tumours with a low apoptotic rate, with more
complete and major responders to the regimen in the high apoptosis
group. The combination of chemotherapy and radiation therapy
induces apoptosis. This was evident from analysis of resection spec-
imens in patients who failed to respond to neoadjuvant therapy. In
these patients, the apoptotic index in 23 of 29 tumours was more
than twice its pre-treatment value. The remaining tumours showed
less of an increase in the apoptotic index (4 cases) or slight reduction
in the percentage of apoptotic cells (2 cases). The pattern of change
in apoptosis was unavailable from patients who had a complete or
major response to therapy, and this is the subject of the current study. 
The biological and molecular response of tumours to neoadju-
vant therapy is not well elucidated. Pre-operative chemoradio-
therapy may modulate tumour growth via induction of apoptosis
and overcome the adverse influence of the biological factors or
genes that usually down-regulate apoptosis. Recent studies indi-
cate that different types of tumour cells undergo programmed cell
death via different pathways. Both p53 (Kagawa et al, 1997) and
bcl-2 (Inada et al, 1997; Miyake et al, 1998; Luo et al, 1999) have
been shown to be key regulators of this process. However, occur-
rence of apoptosis and its modulation via p53 or bcl-2-independent
pathways has also been reported (Xie et al, 1999; Kupryjanczk
et al, 2000). In oesophageal adenocarcinoma the latter scenario is
most likely. We found, for instance, that tumours over-expressing
p53 (before and after chemoradiotherapy) had similar apoptotic
indices to p53-negative tumours. It is possible that immunohisto-
chemically detected p53 might be associated with an accumulation
of functionless protein due to p53 gene mutation. As one of the
normal functions of p53 is to control the cell cycle and apoptosis in
response to DNA damage such as that induced by chemotherapeutic
agents or irradiation, tumour cells with defective p53 might be
less able to repair DNA damage or to undergo apoptosis. The
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Table 3 Apoptotic index, Ki-67 labelling index, p53 and bcl-2 expression in oesophageal adenocarcinoma resection specimens in
patients who did not respond to chemoradiotherapy 
Parameters No. of cases Apoptotic index  P value Ki-67 labelling index  P value 
Mean ± SD/Median Mean ± SD/Median
Labelling index 
pre-CRX 29 0.60 ± 0.29/0.55 38.8 ± 12.0/37.1 
post-CRX 29 1.36 ± 0.47/1.40  < 0.0001 24.7 ± 14.1/26.5 0.0003 
p53 expression 
negative tumours 6 1.33 ± 0.50/1.20  19.0 ± 14.3/18.7 
positive tumours 23 1.37 ± 0.47/1.48 0.78 26.2 ± 14.0/27.1 0.45 
Bcl-2 expression 
negative tumours 22 1.40 ± 0.48/1.44 25.6 ± 14.8/26.4 
positive tumours 7 1.20 ± 0.44/1.31  0.62 22.1 ± 12.7/27.3 0.87 
Tumours differentiation 
well/moderate 25 1.35 ± 0.50/1.31  23.8 ± 15.0/26.3 
poor 4 1.40 ± 0.18/1.40 0.75  30.4 ± 4.5/31.0 0.18 
Tumours extension (pT) 
T1 5 0.90 ± 0.24/0.91 27.2 ± 7.1/27.1 
T2 3 1.29 ± 0.19/1.30 41.8 ± 15.4/36.8 
T3 21 1.48 ± 0.47/1.50 0.02  21.7 ± 13.9/24.3 0.06 
Lymph node metastasis (pN) 
negative 18 1.39 ± 0.51/1.40 20.5 ± 13.8/22.5 
positive 11 1.31 ± 0.40/1.20  0.70 31.7 ± 12.2/31.6 0.008 
CRX = pre-operative chemoradiotherapy; CPR = complete pathological response to CRX; MPR= major pathological response to CRX;
NPR = no pathological response to CRX; P value < 0.05 considered to be significant. heterogeneity of bcl-2 expression in tumour cells was noted in
contrast to p53 which conforms to a homogenous pattern. An
absence of a direct correlation between p53 and bcl-2 expression was
also observed. Moreover, the histological differentiation or stage of
the tumour was not a major determinant of apoptosis, a feature in
contrast to recent reports of ovarian, tongue and colorectal carci-
nomas (Sugamura et al, 1998; Xie et al, 1999; Kupryjanczk et al,
2000). 
Many studies have investigated the link between p53 over-
expression and tumour growth. Some indicated a positive relation-
ship (Augustin et al, 1997; Ikeguchi et al, 1997; Ozer et al, 1998)
and other have failed to establish such an association (Slootweg
et al, 1994; Suto et al, 1998). Ki-67 is a nuclear protein expressed
throughout the cell cycle except in the resting phase (G0) (Gerdes
et al, 1984), and therefore is widely used as a growth marker to
evaluate the proliferation activity of the normal or neoplastic cell
population. In addition, the level of expression of p53 and Ki-67
together Augustin et al, 1997 or independently (Suto et al, 1998)
has been found to correlate well with many clinical and patho-
logical variables. The data presented here indicate the presence of
a significant association between p53 and Ki-67 expression. The
cumulative expression of p53 in tumour biopsy samples was asso-
ciated with an increasing proliferative index as measured by Ki-67
labelling index. The observed correlation between p53 and Ki-67
no longer exists in the resected tumours due to significant decrease
in proliferative index following chemoradiotherapy, while, the
expression level of p53 is largely unchanged. The expression of
p53 and Ki-67 did not impact as predictors of response or resist-
ance to neoadjuvant therapy. Ki-67 expression may, however,
relate to metastatic potential as it correlated with nodal status in
resected specimens, an observation also reported for other tumours
(Ikeguchi et al, 1997; Suto et al, 1998). 
In conclusion, this study demonstrates that apoptosis occurs
among viable tumour cells in all adenocarcinoma cases examined.
Pre-operative chemoradiotherapy significantly increased apoptotic
cell death and significantly decreased cell proliferation rate.
Immunohistochemically detected p53 and  bcl-2 gene products
have no regulatory role in the apoptotic process in oesophageal
adenocarcinoma, nor did they predict response or resistance to the
neoadjuvant regimen. In contrast, a high pre-treatment apoptotic
index correlates with response to neoadjuvant therapy. The evalua-
tion of apoptosis in pre-treatment specimens may have potential
application in predicting the efficacy of neadjuvant approaches for
oesophageal adenocarcinoma. 
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